Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Non-small cell lung cancer (NSCLC) is a common type of cancer with poor prognosis. As individual cancers exhibit unique mutation patterns, identifying and characterizing gene mutations in NSCLC might help predict patient outcomes and guide treatment. The aim of this study was to evaluate the clinical adequacy of molecular testing using next-generation sequencing (NGS) for small biopsy samples and characterize the mutational landscape of Korean patients with advanced NSCLC. Methods: DNA was extracted from small biopsy samples of 162 patients with advanced NSCLC. Targeted NGS of genomic alterations was conducted using Ion AmpliSeq Cancer Hotspot Panel v2. Results: The median age of patients was 64 years (range, 32 to 83 years) and the majority had stage IV NSCLC at the time of cancer diagnosis (90%). Among the 162 patients, 161 patients (99.4%) had novel or hotspot mutations (range, 1 to 21 mutated genes). Mutations were found in 41 genes. Three of the most frequently mutated genes were TP53 (151, 93.2%), KDR (104, 64.2%), and epidermal growth factor receptor (EGFR; 69, 42.6%). We also observed coexistence of EGFR and other oncogene (such as KRAS, PIC3CA, PTEN, and STK11) mutations. Given that 69.6% (48/69) of EGFR mutant patients were treated with EGFR tyrosine kinase inhibitors, EGFR mutant status had higher prognostic ability in this study. Conclusions: These results suggest that targeted NGS using small biopsy samples is feasible and allows for the detection of both common and rare mutations in NSCLC.
Abstract
Background: Non-small cell lung cancer (NSCLC) is a common type of cancer with poor prognosis. As individual cancers exhibit unique mutation patterns, identifying and characterizing gene mutations in NSCLC might help predict patient outcomes and guide treatment. The aim of this study was to evaluate the clinical adequacy of molecular testing using next-generation sequencing (NGS) for small biopsy samples and characterize the mutational landscape of Korean patients with advanced NSCLC. Methods: DNA was extracted from small biopsy samples of 162 patients with advanced NSCLC. Targeted NGS of genomic alterations was conducted using Ion AmpliSeq Cancer Hotspot Panel v2. Results: The median age of patients was 64 years (range, 32 to 83 years) and the majority had stage IV NSCLC at the time of cancer diagnosis (90%). Among the 162 patients, 161 patients (99.4%) had novel or hotspot mutations (range, 1 to 21 mutated genes). Mutations were found in 41 genes. Three of the most frequently mutated genes were TP53 (151, 93.2%), KDR (104, 64.2%), and epidermal growth factor receptor (EGFR; 69, 42.6%). We also observed coexistence of EGFR and other oncogene (such as KRAS, PIC3CA, PTEN, and STK11) mutations. Given that 69.6% (48/69) of EGFR mutant patients were treated with EGFR tyrosine kinase inhibitors, EGFR mutant status had higher prognostic ability in this study. Conclusions: These results suggest that targeted NGS using small biopsy samples is feasible and allows for the detection of both common and rare mutations in NSCLC.
참고문헌 (30)
- 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2016", Cancer Research and Treatment, 48(2), pp.451~457 (2016), 대한암학회
- Chen Z, "Non-small-cell lung cancers: a heterogeneous set of diseases", Nat Rev Cancer, 14, pp.535~546 (2014)[DOI]
- Richer AL, "Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR", Pharmgenomics Pers Med, 8, pp.63~79 (2015)
- Camidge DR, "Acquired resistance to TKIs in solid tumours: learning from lung cancer", Nat Rev Clin Oncol, 11, pp.473~481 (2014)[DOI]
- Han JY, "Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma", Lung Cancer, 85, pp.161~167 (2014)[DOI]
- Rathi V, "Clinical validation of the 50 gene AmpliSeq Cancer Panel V2 for use on a next generation sequencing platform using formalin fixed, paraffin embedded and fine needle aspiration tumour specimens", Pathology, 49, pp.75~82 (2017)[DOI]
- Kris MG, "Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs", JAMA, 311, pp.1998~2006 (2014)[DOI]
- Ballester LY, "Advances in clinical next-generation sequencing: target enrichment and sequencing technologies", Expert Rev Mol Diagn, 16, pp.357~372 (2016)[DOI]
- Padmanabhan V, "Improving adequacy of small biopsy and fine-needle aspiration specimens for molecular testing by next-generation sequencing in patients with lung cancer: a quality improvement study at Dartmouth-Hitchcock Medical Center", Arch Pathol Lab Med, 141, pp.402~409 (2017)[DOI]
- Zheng G, "Test feasibility of next-generation sequencing assays in clinical mutation detection of small biopsy and fine needle aspiration specimens", Am J Clin Pathol, 145, pp.696~702 (2016)[DOI]
- Kim ST, "The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis", Oncotarget, 6, pp.33358~33368 (2015)
- Kim HJ, "Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer", Lung Cancer, 75, pp.321~325 (2012)[DOI]
- Ku BM, "High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma", J Transl Med, 12, pp.299~ (2014)[DOI]
- Lee GD, "MET exon 14 skipping mutations in lung adenocarcinoma: clinicopathologic implications and prognostic Values", J Thorac Oncol, 12, pp.1233~1246 (2017)[DOI]
- Karachaliou N, "KRAS mutations in lung cancer", Clin Lung Cancer, 14, pp.205~214 (2013)[DOI]
- Rosell R, "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial", Lancet Oncol, 13, pp.239~246 (2012)[DOI]
- Kuan FC, "Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis", Br J Cancer, 113, pp.1519~1528 (2015)[DOI]
- Cancer Genome Atlas Research Network, "Comprehensive molecular profiling of lung adenocarcinoma", Nature, 511, pp.543~550 (2014)[DOI]
- Dearden S, "Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)", Ann Oncol, 24, pp.2371~2376 (2013)[DOI]
- Lim SM, "Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)", Oncotarget, 7, pp.36311~36320 (2016)
- Maki-Nevala S, "Hot spot mutations in Finnish non-small cell lung cancers", Lung Cancer, 99, pp.102~110 (2016)[DOI]
- Murakami I, "p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients", Clin Cancer Res, 6, pp.526~530 (2000)
- Lim EH, "Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC)", J Thorac Oncol, 4, pp.12~21 (2009)[DOI]
- Glubb DM, "Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer", Clin Cancer Res, 17, pp.5257~5267 (2011)[DOI]
- Silva IP, "Identification of a novel pathogenic germline KDR variant in melanoma", Clin Cancer Res, 22, pp.2377~2385 (2016)[DOI]
- Roberts PJ, "KRAS mutation: should we test for it, and does it matter?", J Clin Oncol, 31, pp.1112~1121 (2013)[DOI]
- Kim HR, "Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma", Lung Cancer, 83, pp.374~382 (2014)[DOI]
- Pecuchet N, "Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer", Oncotarget, 8, pp.23831~23840 (2017)
- Gleeson FC, "Somatic STK11 and concomitant STK11", KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases, 2015, pp.10, 531~534
- Imielinski M, "Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing", Cell, 150, pp.1107~1120 (2012)[DOI]